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ABSTRACT 
Pharmacological treatments of hypertension are associated with a reduction in cardiovascular risk. 
The blood pressure of both normotensive and hypertensive patients has a particular pattern 
associated to the biological clock set according to a circadian rhythm. One of the aims of this study 
was to test the long acting anti-hypertensive medications, atenolol and perindopril for their 
chronopharmacological properties in their effect on systolic and diastolic blood pressure levels over 
a period of 24 hours when administered in the morning or evening. Other aims were to compare 
blood pressure control in patients on atenolol and perindopril with control and normotensive patients 
and to obtain hourly systolic and diastolic blood pressure values using the ambulatory blood 
pressure monitor. An ambulatory blood pressure monitor was applied to the recruited patients for 
24 hours and results analysed. Atenolol provides better blood pressure control during the early 
morning following a morning dose, whilst it results in an elevated blood pressure during the early 
morning when administered in the evening. Evening administered perindopril did not result in 
optimum blood pressure control throughout the 24h whilst morning administration resulted in an 
elevated early morning peak during the critical early morning period. 
Keywords: chronopharmacology, hypertension, atenolol, perindopril, ambulatory blood pressure 
monitoring. 
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INTRODUCTION 
Pharmacological treatments of hypertension are 
associated with a reduction in cardiovascular risk. 
Treatment should take into consideration the levels of 
the patients' risk factors which may include diabetes, 
cardiovascular or renal damage and target organ 
damage (Blacher et al., 2009). Within the management 
of hypertension, aspects of chronobiology are worth 
considering. 
The blood pressure (BP) of both normotensive and 
hypertensive patients has a particlar pattern 
associated to the body's biological clock set 
according to a circadian rhythm. Anwar et al in 
1998 showed that both the BP and heart rate (HR) of 
both a normotensive and a hypertensive are higher 
during the day and lower during the night. 
Chronobiology as defined by the Dorland's Medical 
Dictionary (26th edition) is the scientific study of 
the effect of time on living systems. 
CHRONOPHARMACOLOGYOF 
ATENOLOL VS PERINDOPRIL 
Atenolol 
Atenolol is a cardioselective, water-soluble ~eta-1 
selective adrenergic antagonist that lacks 
membrane-stabilising properties (BNF, 2010). 
Chronically-administered B-adrenergic antagonists 
have a greater effect on the heart and vasculature 
during the day than during the night. However, they 
appear to be less active at the early morning rise in 
BP, thus will provide inadequate protection during 
the most important time of the day (Lemmer, 1996; 
Morgan et al., 2003). 
In 2002, this was confirmed by a study carried out by 
Cunni. The diastolic BP following an evening dose 
was found to be significantly lower when compared 
to the morning dose (Curmi, 2002). This means that 
an evening dose will result in appropriate decreases 
in BP during the night, leading to a pronounced lack 
of BP control during the early morning hours. 
Perindopril 
Angiotensin-converting enzyme inhibitors (ACEis) 
such as perindopril have achieved widespread usage 
in the treatment of cardiovascular and renal disease. 
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They are adequate in the treatment of hypertension, 
they decrease mortality in congestive heart failure 
and left ventricular dysfunction after myocardial 
infarction, and they delay the progression of diabetic 
nephropathy (Brown et al., 1998). 
In an international study te.sting the chrono-
pharmacological properties of perindopril, 18 male 
patients were analysed after being administered 4mg 
perindopril in the morning (0900h) or at night 
(2100h). Both schedules resulted in a decrease in the 
early morning peak, more prominent following 
evening perindopril administration. Perindopril 
showed an effect greater than 24h after being 
administered at 0900h, while evening administration 
only resulted in an effect of 18h following drug 
administration (Morgan et al., 2007). 
AIMS OF STUDY 
1. To test the long acting anti-hypertensive 
medications, atenolol and perindopril for their 
chronopharmacological properties in their effect 
on systolic and diastolic BP levels over a period 
of 24 hours when administered in the morning 
or evening. Being used on a once daily basis, 
ability to maintain the 24h BP profile is 
evaluated. 
11. To compare patients on atenolol and perindopril 
with control and normotensive patients. 
111. To obtain hourly systolic and diastolic BP values 
using the ambulatory BP monitor. 
METHODOLOGY 
Ethics committee approval and patient informed 
consent were obtained prior to initiating the study. 
Setting of Study 
Patients in Group 1 were recruited from the Medical 
Out-Patients (MOP) of Malta's public hospital and 
from one of the public health centres. 
Criteria for inclusion were as follows: 
• Primary hypertension 
• On once daily atenolol or perindopril to control 
hypertension 
• On no other medication that could influence BP 
• Not older than 75 years. 
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Recruitment of patients 
Weekly sessions were attended at the MOP, where a 
regular consultant physician was always present. 
Patients attended by appointment. 
The investigator discussed with the appropriate 
patient, drug history regarding hypertension and 
then provided information on the study. The 
investigator explained the presence of BP changes 
during the day. The importance of the right dose to 
be taken at an appropriate time was also highlighted. 
Patients were told that since readings were taken 
regularly throughout the 24-hour period, a more 
detailed observation of the BP would be attained. 
An appointment was fixed for each patient, when the 
ambulatory BP monitor (ABPM) was applied for 
twenty-four hours. Upon its removal the following 
day, the time of drug administration was changed to 
the evening or vice versa, for the next six days. 
Exactly a week after the first meeting, a second 
appointment was fixed where the patient was asked to 
perform the 24-hour monitoring again. On the 
following day, data from the two sessions were 
compared in order to conclude whether there were any 
differences in BP when the dose was administered in 
the morning or evening. 
The monitor was set to have a systolic BP (SBP) 
value limit of 140mmHg during the day and of 
120mmHg during the night. The diastolic BP (DBP) 
value limit was set at 90mmHg during the day and 
80mmHg during the night. 
The hourly readings of SBPs and DBPs were 
analysed and whenever a distinctively high reading 
was encountered, the patient was asked what 
activity he/she was performing. This would 
determine whether the high reading was a result of 
exhausting activity. 
An explanation of the results was given to participating 
patients. If readings obtained were above the target for 
BP, the patient was advised on non-pharmacological 
measures and referred to the consultant. 
The patient was advised on how to change the time 
of administration of the antihypertensive medication 
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in order to move on to the second reading. 
Those patients usually taking their dose in the 
morning were told to take half the normal dose in 
the evening of that day, and the other half the next 
morning. Then, on the evening of the following day, 
the normal, full dose was to ·be taken, which was to 
be carried on for the rest of the evenings until the 
second appointment was due. This was done to 
avoid the patient being unprotected for more than 
twenty-four hours and to allow a more subtle way of 
changing the time of dosing. 
Patients who usually take their medication in the 
evening were told to take their dose in the evening 
on that day, and starting as of the following day to 
take their dose in the morning only. 
On the second appointment, the ABPM was fitted 
again and the recorder was set to take hourly 
readings for the next twenty-four hours. The patient 
was asked to return the next day at the same time. 
Subjects taking no antihypertensive 
medications 
Withdrawing medication of the recruited patients 
was not practical due to ethical reasons. Thus, 
separate hypertensive control subjects (Group 2) 
were recruited to use their BP values as a baseline. 
Data from the patient was obtained on his/her 
consent, and non-pharmacological advice was 
given. The criteria for inclusion were: 
• Primary hypertension 
• On no antihypertensive medication 
• On no medication which may influence BP. 
Normotensive subjects (Group 3) were also 
examined to obtain the mean variations of BP in 
Maltese subjects and to show the difference in blood 
pressure variation as compared to control subjects. 
The inclusion criteria were: 
• Do not suffer from any form of hypertension 
• Are on no medication that may affect BP. 
Both groups followed the same procedure as Group 
1 patients. 
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RESULTS 
Four hundred and ninety-seven patients from Group 1 
were screened during weekly sessions at the MOP 
and the health centre between November 2004 and 
November 2006. 
Reasons that led to patients not completing this 
study were: unwilling to participate (26%), change 
of antihypertensive medications (11 %), addition of 
antihypertensive drugs (16%), drop-out after first 
part (31%), lost data due to a technical error (3%), 
travel problems (8%) and invalid ABPM readings 
(5%). 
A total of 43 patients successfully completed this 
study. Twelve were on perindopril (age 55 ± 13.1 
years), 9 on atenolol (age 49.9 ± 11.2 years), 18 
control patients (age 43.2 ± 13.1 years), and 4 
normotensive patients (age 45.6 ± 14.2 years). 
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Atenolol 
Analysis of the 24h Systolic BP (SBP) profile: 
Morning administration 
The SBP during the early morning hours (0600h-
1 OOOh) is well controlled and below the target value 
of 140mmHg. Following atenolol administration at 
0800h, a slight decrease in BP is observed, which 
starts rising again after 0900h. The highest diurnal 
peak presents at 1500h with BP reading 
142.8mmHg, while the lowest peak is seen at 1800h. 
The most pronounced dip at night is oberved at 
0400h, reaching a value of 112mmHg. Figure 1 
compares the 24h SBP profile for patients on 
atenolol administered in the morning or evening. 
Analysis of the 24h SBP profile: Evening 
administration 
A steady morning rise occurs at 0600h, reaching a 
conspicuous peak at 0900h with a reading of 
149.6mmHg. After 0900h, there is a gradual SBP 
decrease, leading to day-time low value period 
--Night --Day 
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 1 2 3 4 5 6 7 
Time (Hours) 
Figure 1. Comparison of the 24h SBP profile for patients on atenolol (n=9) administered in the morning or evening. 
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between 1200h and 1500h. SBP values are kept 
below 140.0mmHg throughout day-time and night-
time. The night-time nadir is reached at 2300h, after 
which BP starts increasing again. 
Analysis of the 24h SBP profile: Morning vs 
Evening administration 
Better SBP control during the early morning period is 
present following morning atenolol administration. 
The majority of peak values during the day-time and 
night-time period are observed from the morning 
administration group. Neither morning nor evening 
drug administration resulted in a prominent 
nocturnal dip of 10% or more when compared to 
day-time values (7.8% and 7.2% respectively). 
Analysis of the 24h Diastolic BP (DBP) profile: 
Morning administration 
The rise in DBP starts after 0400h, producing a peak 
at 0500h and decreasing again at 0700h. A steep rise 
is observed after 0700h, leading to the morning peak 
at 0900h. DBP values throughout day-time are lower 
than the morning peak with a gradual BP decrease 
during 2200h and 0400h. 
Analysis of the 24h DBP profile: Evening 
administration 
A steep morning rise which was observed at 0600h 
results in the highest diurnal peak at 0900h of 
97 .lmmHg. A sharp decrease in DBP follows till 
llOOh, after which a more stable pattern is obtained 
between 1130h and 2100h. A gradual DBP decrease 
is noted after administration at 2000h, resulting in a 
night-time nadir at 2400h. 
Analysis of the 24h DBP profile: Morning vs 
Evening administration 
The DBP pattern following morning administration 
showed · more changes throughout the day when 
compared to the evening dosing group. Both 
resulted in elevated early morning peaks at 0900h, 
followed by a decline in DBP. Evening drug dosing 
resulted in lower night-time values until 0200h, after 
which values becomes similar to the other cohort. 
Evening administration resulted in a 10% decrease 
in day-time pressure during the night-time period, 
resulting in a dipper status unlike morning 
administration (9 .0%). 
Perindopril 
Analysis of the 24h SBP profile: Morning 
administration 
An immediate sharp rise in SBP is observed at 
0500h, reaching a peak of 145.9mmHg at 0800h. A 
sharp decline is noted following perindopril dosing 
at 0800h, reaching a value of 126.5mmHg at IOOOh. 
Elevated readings are observed between 1500h and 
2000h, with a decrease to night-time pressure 
starting after 1700h. Nadir was reached at 0300h 
with a value of 108.lmmHg. 
Analysis of the 24h SBP profile: Evening 
administration 
A gradual rise in SBP occured after 0 I OOh. During the 
early morning readings are kept under 140.0mmHg 
and no rapid rise is observed. SBP elevation is 
observed between 1500h and 2000h, with a gradual 
decrease towards lower night-time values starting at 
1800h. Nadir was reached at OIOOh. 
Analysis of the 24h SBP profile: Morning vs 
Evening administration 
The 0800h peak rise of morning administration was 
16.3mmHg more than that following evening dosing. 
However, this finding was not statistically different 
(p=0.3750; Wilcoxon test). During day-time, SBP 
following evening administration was generally 
higher than morning administration. Evening dosing 
managed to achieve a dipper status (12.6% compared 
to 8.2% following morning dosing). 
Analysis of the 24 DBP profile: Morning 
administration 
A gradual increase in DBP started at 0200h, 
resulting in an elevated peak at 0800h. DBP values 
fell following morning administration at 0800h, 
reaching low values between IOOOh and llOOh. 
DBP elevation is observed between 1500h and 
1900h. BP decline in preparation to night-time 
values started at 1700h, reaching in stable low 
readings during the night. 
Analysis of the 24 DBP profile: Evening 
administration 
The morning peak following evening dosing is 
observed at IOOOh, with a reading of 93.0mmHg. 
During the early morning (before IOOOh), values 
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below 85 .OmmHg are acheived. A general DBP 
elevation is noted between 1500h and 2100h. The 
highest diurnal peak is observed at 1800h, followed 
by a decline that continues after dosing at 2000h. 
DBP is kept constant throughout night-time, except 
at 0300h. 
Analysis of the 24 DBP profile: Morning vs 
Evening administration 
A BP difference of 14.3mmHg is present between 
both regimens at 0800h. Both morning and evening 
perindopril administration led to evident nocturnal 
dips, reaching DBP decreases of 13.4% and 14.6% 
respectively. 
Comparing Atenolol, Perindopril, 
Control and Normotensive subjects 
Analysis of the 24h SBP profile: Morning 
administration 
A 5% significant difference is present at 0800h 
when the perindopril and control group are 
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compared to the normotensive group (p=0.0046 and 
p=0.0080, respectively; Paired t-test). The normo-
tensive group, when compared to the other 3 groups 
is on the whole markedly lower throughout the day 
(p=0.300; one-way ANOVA). The paired t-test 
performed on whole day results in a statistical 
difference between the control and normotensive 
group (p=O .0041). Figure 2 below shows the 24h 
SBP patterns of morning administered perindopril, 
control, and normotensive groups. 
Atenolol is found to present more BP changes 
throughout the day than perindopril. Perindopril 
results in lower SBP control during the early 
morning period. 
The highest peak reached amongst all four groups is 
that of perindopril at 0800h (152.6mmHg), whilst 
the lowest dip noted at 0200h resulted from the 
normotensive group (93.6mmHg). At 1800h, the 
atenolol group is significantly lower than the control 
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Figure 2. The 24h SBP patterns of morning administered perindopril (n=12), control (n=18) and normotensive (n=5) 
groups. 
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group (p=0.0071); Paired t-test). The control group 
is significantly higher than the normotensive group 
at 0400h (p=0.0046; Paired t-test) and 0600h 
(p=0.0094; Paired t-test). 
The SBP profile during the day-time period of the 
normotensive group is similar to the treatment 
groups, however different from the control group. 
Statistical analysis of the four groups for the night-
time period does not show any difference between 
the groups. 
Analysis of the 24h SBP profile: Evening 
administration 
The highest peak throughout the day of both the 
normotensive and atenolol group occured at 0900h 
having values of 132.0mmHg and 149.6mmHg 
respectively. One-way ANOVA showed that the 
overall SBP profile of the normotensive group is 
generally lower than the other groups and is almost 
significantly different (p=0.0684). 
The lowest night-time nadir is reached by the 
normotensive group at 0200h, with a value of 
93.6mmHg. At 0400h a significant difference is 
observed between the control and normotensive 
group (p=0.0047; Paired t-test). 
During the day-time period, this effect is reversed 
since the perindopril group appears to have more 
frequent higher readings than atenolol when compared 
to the control group. The elevated perindopril pattern 
is noted towards the time of dosing. 
Perindopril presents with a smoother curve 
throughout the day when compared to atenolol. 
Perindopril also presented with better SBP control 
during the early morning hours, however resulted in 
an elevated pattern during most of the day-time 
period till dosing time, when compared to atenolol. 
Both are similar throughout the day and do not differ. 
Analysis of the 24h DBP profile: Morning 
administration 
The lowest DBP value noted during the day-time 
period in all the four groups was from atenolol at 
1300h, with a value of 67 .6mmHg. The 
normotensive group is more similar to the other 
139 
groups when the DBP mean values are compared. 
The lowest DBP value during the night is observed 
at 0400h by the normotensive group (55.0mmHg). 
The DBP values of all groups decrease during the 
night with readings ranging from 55.0- 82.6mmHg. 
Analysis of the 24h DBP profile: Evening 
administration 
Both atenolol and the normotensive groups showed 
an early morning peak at 0900h, which is similarly 
followed by the control group an hour later. 
Perindopril, when compared to the control and 
normotensive groups, results in the best DBP control 
during the early morning period with a lack of rapid 
rise in DBP. 
At 1800h, a statistically significant difference 
amongst the four groups is almost detected 
(p=0.0618; one-way ANOVA), while a statistical 
difference at the 10% level is detected between the 
perindopril and atenolol group (p=0.0138; Paired t-
test). 
Atenolol results in a lower profile during the day-
time, especially during the last few hours before 
drug administration. Atenolol, unlike perindopril, 
results in a steep morning surge during the early 
morning period. 
CONCLUSION 
Atenolol administered in the evening presents a 
drawback since it results in an elevated BP during 
the early morning as well as a lack of adequate 
nocturnal dip in SBP. Atenolol provides better BP 
control during the early morning following a 
morning dose. 
Evening administered perindopril did not result in 
optimum BP control throughout the 24h whilst 
morning administration resulted in an elevated early 
morning peak during the critical early morning 
period. 
This study shows the value of ambulatory BP 
monitoring in the management of hypertension.lt is 
of support to physicians and pharmacists during 
patient monitoring and decision-making processes 
for pharmacotherapeutic interventions. 
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